supernus pharmaceuticals inc
(SUPN:NASDAQ GM)
supernus pharmaceuticals inc (SUPN) Snapshot
|
Open
$6.64
|
Previous Close
$6.67
|
|
|
Day High
$6.78
|
Day Low
$6.59
|
|
|
52 Week High
07/19/12 - $16.68
|
52 Week Low
04/25/13 - $4.45
|
|
|
Market Cap
207.9M
|
Average Volume 10 Days
259.6K
|
|
|
EPS TTM
$-2.27
|
Shares Outstanding
31.0M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
supernus pharmaceuticals inc (SUPN) Related Businessweek News
No Related Businessweek News Foundsupernus pharmaceuticals inc (SUPN) Details
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
supernus pharmaceuticals inc (SUPN) Top Compensated Officers
supernus pharmaceuticals inc (SUPN) Key Developments
Supernus Pharmaceuticals, Inc. received a tentative approval letter from the Food & Drug Administration for Trokendi XR(TM), a novel once-daily extended release formulation of topiramate (formerly known as SPN-538). The letter states that the FDA completed its review of the Trokendi XR(TM) New Drug Application as amended in December 2012 and the product is tentatively approved for use as recommended in the submitted and agreed-upon labeling.
Supernus Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-04-2013 10:00 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Jack A. Khattar, Founder, Chief Executive Officer, President and Director.
Supernus Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of $147,000 against $208,000 a year ago. Operating loss was $17,908,000 against $7,878,000 a year ago. Net loss was $18,414,000 against $9,277,000 a year ago. Net loss attributable to common shareholders was $18,414,000 or $0.60 per basic and diluted sharer against $10,135,000 or $6.05 per basic and diluted sharer a year ago. For the year 2013, In order to support both product launches and the continued development of the company's pipeline, the company projected cash burn for 2013 to range from $85 million to $95 million. The decrease of $10 million in projected cash burn from prior projection of $95 million to $105 million is primarily due to the refinancing of secured credit facility.

| Recently Viewed | |||
| SUPN:US | $6.71 USD | +0.04 | |
| Company | Last | Change | |
| No competitor information is available for SUPN. | |||
| View Industry Companies | |||
Industry Analysis
SUPN
Industry Average
| Valuation | SUPN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 145.1x |
|
| Price/Book | 5.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 82.2x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








